{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:53:31Z","timestamp":1791136411770,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"DOI":"10.1007\/s11523-026-01259-4","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:29:38Z","timestamp":1791134978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Contraindication-Based Selection: The Unmet Need for Predictive Biomarkers in First-Line Immunotherapy for Advanced HCC"],"prefix":"10.1007","author":[{"given":"Alireza","family":"Tojjari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-9401","authenticated-orcid":false,"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,4]]},"reference":[{"issue":"20","key":"1259_CR1","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"key":"1259_CR2","doi-asserted-by":"publisher","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070. https:\/\/doi.org\/10.1056\/EVIDoa2100070.","DOI":"10.1056\/EVIDoa2100070"},{"issue":"10492","key":"1259_CR3","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025;405(10492):1851\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(25)00403-9.","journal-title":"Lancet"},{"issue":"15","key":"1259_CR4","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.23.02745","volume":"42","author":"JD Gordan","year":"2024","unstructured":"Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J Clin Oncol. 2024;42(15):1830\u201350. https:\/\/doi.org\/10.1200\/JCO.23.02745.","journal-title":"J Clin Oncol"},{"key":"1259_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114148","volume":"207","author":"MA Lopez-Olivo","year":"2024","unstructured":"Lopez-Olivo MA, Kachira JJ, Abdel-Wahab N, Pundole X, Aldrich JD, Carey P, et al. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease. Eur J Cancer. 2024;207:114148. https:\/\/doi.org\/10.1016\/j.ejca.2024.114148.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1259_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/liv.15419","volume":"43","author":"S Kayali","year":"2023","unstructured":"Kayali S, Pasta A, Plaz Torres MC, Jaffe A, Strazzabosco M, Marenco S, et al. Immune checkpoint inhibitors in malignancies after liver transplantation: a systematic review and pooled analysis. Liver Int. 2023;43(1):8\u201317. https:\/\/doi.org\/10.1111\/liv.15419.","journal-title":"Liver Int"},{"issue":"9_Suppl.","key":"1259_CR7","doi-asserted-by":"publisher","first-page":"S1463","DOI":"10.1016\/j.annonc.2022.10.115","volume":"33","author":"A Vogel","year":"2022","unstructured":"Vogel A, Chan S, Furuse J, Tak W, Masi G, Varela M, et al. 79P outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study. Ann Oncol. 2022;33(9_Suppl.):S1463\u20134. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.115.","journal-title":"Ann Oncol"},{"issue":"5","key":"1259_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1159\/000529996","volume":"12","author":"M Kudo","year":"2023","unstructured":"Kudo M, Finn RS, Cheng A-L, Zhu AX, Ducreux M, Galle PR, et al. Albumin-bilirubin grade analyses of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: a post hoc analysis of the phase III IMbrave150 Study. Liver Cancer (Basel). 2023;12(5):479\u201393. https:\/\/doi.org\/10.1159\/000529996.","journal-title":"Liver Cancer (Basel)"},{"issue":"3","key":"1259_CR9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","volume":"75","author":"M Kudo","year":"2021","unstructured":"Kudo M, Matilla A, Santoro A, Melero I, Graci\u00e1n AC, Acosta-Rivera M, et al. CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 2021;75(3):600\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2021.04.047.","journal-title":"J Hepatol"},{"key":"1259_CR10","doi-asserted-by":"publisher","unstructured":"Terashima T, Ikeda M, Yamashita T, Okusaka T, Imaoka H, Kawaoka T, et al. A multicenter phase II study on atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma and Child-Pugh Classification B cirrhosis: CHALLENGE Trial. Liver Cancer. 2026. Epub ahead of print. https:\/\/doi.org\/10.1159\/000551476.","DOI":"10.1159\/000551476"},{"issue":"1","key":"1259_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/cam4.4906","volume":"12","author":"WJ Chapin","year":"2023","unstructured":"Chapin WJ, Hwang WT, Karasic TB, McCarthy AM, Kaplan DE. Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child\u2010Pugh B cirrhosis. Cancer Med. 2023;12(1):189\u201399. https:\/\/doi.org\/10.1002\/cam4.4906.","journal-title":"Cancer Med"},{"issue":"9","key":"1259_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2026.101915","volume":"8","author":"AV Odent","year":"2026","unstructured":"Odent AV, Campani C, Bouattour M, Touchefeu Y, Delhoume V, Rosmorduc O, et al. Clinical predictors of response to atezolizumab\/bevacizumab in Child-Pugh B patients with hepatocellular carcinoma. JHEP Rep. 2026;8(9):101915. https:\/\/doi.org\/10.1016\/j.jhepr.2026.101915.","journal-title":"JHEP Rep"},{"issue":"10","key":"1259_CR13","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1007\/s00432-023-04678-2","volume":"149","author":"M Rimini","year":"2023","unstructured":"Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, et al. Survival outcomes from atezolizumab plus bevacizumab versus lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. J Cancer Res Clin Oncol. 2023;149(10):7565\u201377. https:\/\/doi.org\/10.1007\/s00432-023-04678-2.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"1259_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.21873\/cdp.10295","volume":"4","author":"A Kuwano","year":"2024","unstructured":"Kuwano A, Yada M, Tanaka K, Koga Y, Nagasawa S, Masumoto A, et al. Systemic chemotherapy for advanced hepatocellular carcinoma in patients with Child-Pugh class B. Cancer Diagn Progn. 2024;4(2):111\u20136. https:\/\/doi.org\/10.21873\/cdp.10295.","journal-title":"Cancer Diagn Progn"},{"issue":"7854","key":"1259_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, Nunez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450\u20136. https:\/\/doi.org\/10.1038\/s41586-021-03362-0.","journal-title":"Nature"},{"key":"1259_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2026.05.004","author":"M Feng","year":"2026","unstructured":"Feng M, Granito A. Foxp3+ Tregs in HCC immunity and immunotherapy. Trends Mol Med. 2026. https:\/\/doi.org\/10.1016\/j.molmed.2026.05.004.","journal-title":"Trends Mol Med"},{"key":"1259_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2026.104075","volume":"52","author":"Y Li","year":"2026","unstructured":"Li Y, Tan X, Fang S, So C. Differential efficacy of immunotherapy for hepatocellular carcinoma by aetiology: a systematic review and meta-analysis. Clin Oncol. 2026;52:104075. https:\/\/doi.org\/10.1016\/j.clon.2026.104075.","journal-title":"Clin Oncol"},{"issue":"8","key":"1259_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41571-026-01160-z","volume":"23","author":"JM Llovet","year":"2026","unstructured":"Llovet JM, Mauro E, Rimassa L, Mazzaferro V, Pinter M, Kelley RK, et al. Trial design and end points in hepatocellular carcinoma: an EASL\u2013AASLD\u2013ILCA consensus statement. Nat Rev Clin Oncol. 2026;23(8):619\u201347. https:\/\/doi.org\/10.1038\/s41571-026-01160-z.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"1259_CR19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41571-023-00816-4","volume":"20","author":"TF Greten","year":"2023","unstructured":"Greten TF, Villanueva A, Korangy F, Ruf B, Yarchoan M, Ma L, et al. Biomarkers for immunotherapy of hepatocellular carcinoma. Nat Rev Clin Oncol. 2023;20(11):780\u201398. https:\/\/doi.org\/10.1038\/s41571-023-00816-4.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1259_CR20","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu AX, Abbas AR, De Galarreta MR, Guan Y, Lu S, Koeppen H, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28(8):1599\u2013611. https:\/\/doi.org\/10.1038\/s41591-022-01868-2.","journal-title":"Nat Med"},{"issue":"2","key":"1259_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","volume":"76","author":"B Scheiner","year":"2022","unstructured":"Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy: development and validation of the CRAFITY score. J Hepatol. 2022;76(2):353\u201363. https:\/\/doi.org\/10.1016\/j.jhep.2021.09.035.","journal-title":"J Hepatol"},{"issue":"24","key":"1259_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17243891","volume":"17","author":"T Kuzuya","year":"2025","unstructured":"Kuzuya T, Muto H, Tachi Y, Kobayashi M, Sugiyama H, Ariga M, et al. Biomarker-based responder selection and early prediction of treatment response in hepatocellular carcinoma: dynamic changes in alpha-fetoprotein and des-gamma-carboxy prothrombin during atezolizumab plus bevacizumab therapy. Cancers. 2025;17(24):3891. https:\/\/doi.org\/10.3390\/cancers17243891.","journal-title":"Cancers"},{"issue":"5","key":"1259_CR23","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/jso.27825","volume":"131","author":"NX Tocci","year":"2025","unstructured":"Tocci NX, Wehrle CJ, Sun K, Jiao C, Hong H, Gross A, et al. Circulating tumor DNA in management of primary liver malignancy: a review of the literature and future directions. J Surg Oncol. 2025;131(5):879\u201387. https:\/\/doi.org\/10.1002\/jso.27825.","journal-title":"J Surg Oncol"},{"issue":"3","key":"1259_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/14737159.2022.2049244","volume":"22","author":"A Muhammed","year":"2022","unstructured":"Muhammed A, D\u2019Alessio A, Enica A, Talbot T, Fulgenzi CAM, Nteliopoulos G, et al. Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. Expert Rev Mol Diagn. 2022;22(3):253\u201364. https:\/\/doi.org\/10.1080\/14737159.2022.2049244.","journal-title":"Expert Rev Mol Diagn"},{"issue":"40","key":"1259_CR25","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.18632\/oncotarget.26998","volume":"10","author":"C Ang","year":"2019","unstructured":"Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019;10(40):4018\u201325. https:\/\/doi.org\/10.18632\/oncotarget.26998.","journal-title":"Oncotarget"},{"issue":"2_Suppl.","key":"1259_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.LBA479","volume":"44","author":"PR Galle","year":"2026","unstructured":"Galle PR, Sangro B, Decaens T, Kudo M, Qin S, Fonseca LD, et al. Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): 4-year follow-up of CheckMate 9DW. J Clin Oncol. 2026;44(2_Suppl.):LBA479. https:\/\/doi.org\/10.1200\/JCO.2026.44.2_suppl.LBA479.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1259_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1159\/000542285","volume":"14","author":"YJ Kim","year":"2025","unstructured":"Kim YJ, Merle P, Finn RS, Kudo M, Kl\u00fcmpen HJ, Lim HY, et al. Regorafenib for hepatocellular carcinoma in real-world practice (REFINE): a prospective, observational study. Liver Cancer. 2025;14(4):391\u2013407. https:\/\/doi.org\/10.1159\/000542285.","journal-title":"Liver Cancer"},{"issue":"8","key":"1259_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2026.101893","volume":"8","author":"E Akkus","year":"2026","unstructured":"Akkus E, Hobeika C, Edeline J, Hollande C, Allaire M, Amaddeo G, et al. Second-line TKI after first-line immunotherapy-based treatment in advanced HCC: reconstructed IPD meta-analysis. JHEP Rep. 2026;8(8):101893. https:\/\/doi.org\/10.1016\/j.jhepr.2026.101893.","journal-title":"JHEP Rep"},{"key":"1259_CR29","doi-asserted-by":"publisher","unstructured":"Peck-Radosavljevic M, Abdelgafur A, Granito A, Gasbarrini A, Ma YT, Mena E, et al. An international phase 4 study of lenvatinib and sorafenib in real-world patients with unresectable hepatocellular carcinoma: final analysis. Liver Cancer. 2026. Epub ahead of print. https:\/\/doi.org\/10.1159\/000552115.","DOI":"10.1159\/000552115"},{"issue":"8","key":"1259_CR30","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S2468-1253(26)00115-9","volume":"11","author":"P Merle","year":"2026","unstructured":"Merle P, Blanc J-F, Le Malicot K, Peron J-M, Bourgeois V, Bouattour M, et al. Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2\u20133 trial. Lancet Gastroenterol Hepatol. 2026;11(8):700\u201312. https:\/\/doi.org\/10.1016\/S2468-1253(26)00115-9.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01259-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:29:39Z","timestamp":1791134979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01259-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,4]]},"references-count":30,"alternative-id":["1259"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01259-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,4]]},"assertion":[{"value":"26 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anwaar Saeed reports an advisory board role with AstraZeneca, Bristol-Myers Squibb, Merck, Exelixis, Pfizer, Xilio Therapeutics, Taiho, Amgen, Autem Therapeutics, KAHR Medical, Arcus Therapeutics, Regeneron, Replimune, BeONE, and Exact Sciences; institutional research funding from AstraZeneca, Bristol-Myers Squibb, Merck, Exelixis, Actuate Therapeutics, Incyte Corporation, Oxford Biotherapeutics, Replimune, Phanes Therapeutics, Arcus Therapeutics, Regeneron, Henlius, Coherus Oncology, and KAHR medical. Alireza Tojjaria has no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analyzed for this article. All information discussed in the article is derived from publicly available published sources.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: AS and AT; writing (original draft): AT; review and editing: AT and AS; supervision: AS. Both authors reviewed and approved the final manuscript and agree to be accountable for the work.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}